Ionis Pharmaceuticals, Inc. (IONS) Dividend History

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Founded in 1989, the company focuses on using antisense technology to develop medicines for various diseases, including neurological, rare, and severe conditions. Ionis is known for its innovative approach to addressing unmet medical needs through gene-silencing strategies.

2855 Gazelle Court, Carlsbad, CA, 92010
Phone: (760) 931-9200
Website: https://www.ionispharma.com

Dividend History

Ionis Pharmaceuticals, Inc. currently does not pay dividends

Company News

Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

GlobeNewswire Inc.

Featured Companies: ATXS CAMP KALV NTLA
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines, a clinical-stage biopharmaceutical company, will present data from its four late-stage programs in epilepsy and movement disorders at the American Academy of Neurology 2025 Annual Meeting. The company's innovative pipeline includes therapies for central nervous system disorders, with a focus on neuronal excitation-inhibition imbalance.

GlobeNewswire Inc.

Featured Companies: PRAX
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment

BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.

GlobeNewswire Inc.

Featured Companies: ABBV BMY GSKH MRK PTGX
Ionis Pharma Beats Expectations for Q4

Ionis Pharmaceuticals, a leader in RNA-targeted drug discovery, reported better-than-expected revenue and a smaller-than-expected loss in Q4 2024. The company's recent product launches, including Wainua and Tryngolza, contributed to the positive results, and it plans to continue investing in its pipeline and product launches in 2025.

The Motley Fool
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034

The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.

GlobeNewswire Inc.

Featured Companies: ALNY BNTC XLO

Dividend data last updated 06/07/2025 10:18:18 UTC